EMERGENT BIOSOLUTIONS INC. Revenue
EMERGENT BIOSOLUTIONS INC. (EBS) reported Revenue of $742.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. revenues for the quarter ending 2024-12-31 was $194.70M, a 29.61% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenues for the quarter ending 2024-09-30 was $293.80M, a 8.61% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenues for the quarter ending 2024-06-30 was $254.70M, a 24.62% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenues for the quarter ending 2024-03-31 was $300.40M, a 82.84% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. revenues for fiscal 2025 was $742.90M, a 28.81% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. revenues for fiscal 2024 was $1.04B, a 0.54% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. revenues for fiscal 2023 was $1.05B, a 6.10% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. revenues for fiscal 2022 was $1.12B, a 36.99% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $742.90M 10-K · filed 2026-02-27 | |||||||
| 2024-12-31 | $194.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $488.50M derived: sum of 2 quarters · filed 2026-02-27 | $743.20M derived: sum of 3 quarters · filed 2026-02-27 | $1.04B 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $293.80M 10-Q · filed 2024-11-07 | $548.50M derived: sum of 2 quarters · filed 2024-11-07 | $848.90M 10-Q · filed 2024-11-07 | $1.13B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | $254.70M 10-Q · filed 2024-08-07 | $555.10M 10-Q · filed 2024-08-07 | $831.70M derived: sum of 3 quarters · filed 2026-02-27 | $1.10B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $300.40M 10-Q · filed 2024-05-02 | $577.00M derived: sum of 2 quarters · filed 2026-02-27 | $847.50M derived: sum of 3 quarters · filed 2026-02-27 | $1.19B derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | $276.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $547.10M derived: sum of 2 quarters · filed 2026-02-27 | $885.00M derived: sum of 3 quarters · filed 2026-02-27 | $1.05B 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $270.50M 10-Q · filed 2024-11-07 | $608.40M derived: sum of 2 quarters · filed 2024-11-07 | $772.70M 10-Q · filed 2024-11-07 | $1.10B derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $337.90M 10-Q · filed 2024-08-07 | $502.20M 10-Q · filed 2024-08-07 | $503.00M 10-Q · filed 2023-08-09 | $832.40M derived: sum of 3 quarters · filed 2024-08-07 | $1.07B derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | $164.30M 10-Q · filed 2024-05-02 | $165.10M 10-Q · filed 2023-05-10 | $494.50M derived: sum of 2 quarters · filed 2024-05-02 | $734.40M derived: sum of 3 quarters · filed 2024-05-02 | $977.00M derived: sum of 4 quarters · filed 2024-05-02 | |||
| 2022-12-31 | $330.20M 10-K/A · filed 2023-12-11 | $570.10M derived: sum of 2 quarters · filed 2023-12-11 | $812.70M derived: sum of 3 quarters · filed 2023-12-11 | $1.12B 10-K · filed 2025-03-04 | $1.12B 10-K · filed 2023-03-01 | |||
| 2022-09-30 | $239.90M 10-K/A · filed 2023-12-11 | $240.00M 10-Q · filed 2022-11-09 | $482.50M derived: sum of 2 quarters · filed 2023-12-11 | $787.30M 10-Q · filed 2023-12-11 | $790.20M 10-Q · filed 2022-11-09 | $1.52B derived: sum of 4 quarters · filed 2023-12-11 | ||
| 2022-06-30 | $242.60M 10-K/A · filed 2023-12-11 | $242.70M 10-Q · filed 2022-08-02 | $550.20M 10-Q · filed 2023-08-09 | $1.28B derived: sum of 3 quarters · filed 2023-12-11 | $1.57B derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2022-03-31 | $304.80M 10-K/A · filed 2023-12-11 | $307.50M 10-Q · filed 2022-04-29 | $1.04B derived: sum of 2 quarters · filed 2023-12-11 | $1.32B derived: sum of 3 quarters · filed 2023-12-11 | $1.70B derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-12-31 | $732.90M 10-K/A · filed 2023-12-11 | $1.02B derived: sum of 2 quarters · filed 2023-12-11 | $1.40B derived: sum of 3 quarters · filed 2023-12-11 | $1.77B 10-K · filed 2024-03-08 | $1.79B 10-K · filed 2022-02-25 | |||
| 2021-09-30 | $286.30M 10-K/A · filed 2023-12-11 | $329.00M 10-Q · filed 2021-11-05 | $663.70M derived: sum of 2 quarters · filed 2023-12-11 | $1.07B 10-Q · filed 2022-11-09 | $1.65B derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-06-30 | $377.40M 10-K/A · filed 2023-12-11 | $397.50M 10-Q · filed 2022-08-02 | $740.50M 10-Q · filed 2022-08-02 | $1.36B derived: sum of 3 quarters · filed 2023-12-11 | $1.74B derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-03-31 | $377.00M 10-K/A · filed 2023-12-11 | $343.00M 10-Q · filed 2022-04-29 | $981.90M derived: sum of 2 quarters · filed 2023-12-11 | $1.37B derived: sum of 3 quarters · filed 2023-12-11 | ||||
| 2020-12-31 | $604.90M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $990.10M derived: sum of 2 quarters · filed 2023-12-11 | $1.58B 10-K/A · filed 2023-12-11 | $1.56B 10-K · filed 2022-02-25 | ||||
| 2020-09-30 | $385.20M 10-Q · filed 2021-11-05 | $972.40M 10-Q · filed 2021-11-05 | ||||||
| 2019-12-31 | $1.11B 10-K · filed 2022-02-25 | |||||||
| 2016-03-31 | $111.00M 10-Q · filed 2016-05-06 | $279.11M derived: sum of 2 quarters · filed 2016-05-06 | $444.05M derived: sum of 3 quarters · filed 2016-05-06 | $570.16M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2015-12-31 | $168.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $333.04M derived: sum of 2 quarters · filed 2016-02-29 | $459.16M derived: sum of 3 quarters · filed 2016-02-29 | $522.79M 10-K · filed 2016-02-29 | ||||
| 2015-09-30 | $164.94M 10-Q · filed 2015-11-06 | $291.05M derived: sum of 2 quarters · filed 2015-11-06 | $354.69M 10-Q · filed 2015-11-06 | $502.66M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2015-06-30 | $126.11M 10-Q · filed 2015-08-06 | $189.75M 10-Q · filed 2015-08-06 | $337.72M derived: sum of 3 quarters · filed 2016-05-06 | $475.67M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2015-03-31 | $63.63M 10-Q · filed 2016-05-06 | $211.61M derived: sum of 2 quarters · filed 2016-05-06 | $349.56M derived: sum of 3 quarters · filed 2016-05-06 | $459.89M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2014-12-31 | $147.97M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $285.93M derived: sum of 2 quarters · filed 2016-02-29 | $396.25M derived: sum of 3 quarters · filed 2016-02-29 | $450.14M 10-K · filed 2016-02-29 | ||||
| 2014-09-30 | $137.95M 10-Q · filed 2015-11-06 | $248.28M derived: sum of 2 quarters · filed 2015-11-06 | $302.16M 10-Q · filed 2015-11-06 | $400.27M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $110.33M 10-Q · filed 2015-08-06 | $164.21M 10-Q · filed 2015-08-06 | $262.32M derived: sum of 3 quarters · filed 2016-02-29 | $351.42M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $53.88M 10-Q · filed 2015-05-08 | $151.99M derived: sum of 2 quarters · filed 2016-02-29 | $241.09M derived: sum of 3 quarters · filed 2016-02-29 | $323.53M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $98.11M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $187.21M derived: sum of 2 quarters · filed 2016-02-29 | $269.64M derived: sum of 3 quarters · filed 2016-02-29 | $312.75M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $89.10M 10-Q · filed 2014-11-10 | $171.54M derived: sum of 2 quarters · filed 2014-11-10 | $214.64M 10-Q · filed 2014-11-10 | $309.24M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $82.44M 10-Q · filed 2014-08-08 | $125.54M 10-Q · filed 2014-08-08 | $220.14M derived: sum of 3 quarters · filed 2015-03-09 | $286.73M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | $43.10M 10-Q · filed 2014-05-12 | $137.71M derived: sum of 2 quarters · filed 2015-03-09 | $204.30M derived: sum of 3 quarters · filed 2015-03-09 | $274.68M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $94.61M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $161.20M derived: sum of 2 quarters · filed 2015-03-09 | $231.58M derived: sum of 3 quarters · filed 2015-03-09 | $281.89M 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $66.59M 10-Q · filed 2013-11-08 | $136.97M derived: sum of 2 quarters · filed 2013-11-08 | $187.28M 10-Q · filed 2013-11-08 | $295.23M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $70.38M 10-Q · filed 2013-08-06 | $120.69M 10-Q · filed 2013-08-06 | $228.64M derived: sum of 3 quarters · filed 2014-03-10 | $287.40M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | $50.31M 10-Q · filed 2013-05-03 | $158.26M derived: sum of 2 quarters · filed 2014-03-10 | $217.02M derived: sum of 3 quarters · filed 2014-03-10 | $305.16M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $107.95M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $166.71M derived: sum of 2 quarters · filed 2014-03-10 | $254.85M derived: sum of 3 quarters · filed 2014-03-10 | $273.38M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $58.76M 10-Q · filed 2012-11-01 | $146.90M derived: sum of 2 quarters · filed 2012-11-01 | $165.44M 10-Q · filed 2012-11-01 | |||||
| 2011-06-30 | $88.14M 10-Q · filed 2012-08-03 | $106.67M 10-Q · filed 2012-08-03 | ||||||
| 2010-12-31 | $286.17M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |